NCT06761677 2026-02-05
A Phase 1b/2 Study of Intravenous Brincidofovir in Patients With Relapsed or Refractory Lymphoma and Relapsed or Refractory Extranodal Natural Killer/T-cell Lymphoma
SymBio Pharmaceuticals
Phase 1/2 Suspended
SymBio Pharmaceuticals
Bristol-Myers Squibb
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Washington University School of Medicine